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Abstract
Aim Soluble suppression of tumorigenicity-2 (sST2) is a strong prognostic biomarker in heart failure. The emerging under-
standing of circadian biology in cardiovascular disease may lead to novel applications in prognosis and diagnosis and may pro-
vide insight into mechanistic aspects of the disease–biomarker interaction. So far, it is unknown whether sST2 exhibits a
diurnal rhythm. Repeated measurements of sST2 may aid in clinical decision making. The goal of this study was to investigate
whether sST2 exhibits diurnal variation in patients with heart failure with reduced ejection fraction (HFrEF) and in control sub-
jects, thereby enhancing its diagnostic and prognostic values.
Methods and results The study comprised 32 subjects: 16 HFrEF patients and 16 controls. Blood was collected at seven sub-
sequent time points during a 24 h time period. sST2, N-terminal pro-B-type natriuretic peptide (NT-proBNP), melatonin, and
cortisol were measured from serum. Peak values of sST2 clustered at daytime (modal value: 5 p.m.) in 87.6% of all subjects
(81.3% of patients, P = 0.021; 93.8% of controls, P = 0.001), and minimum concentrations at night-time (modal value: 5 a.
m.) in 84.4% (87.5% of patients, P = 0.004 81.3% of controls, P = 0.021). A cosinor analysis of mean normalized sST2 values
revealed significant cosine shaped 24 h oscillations of patients (P = 0.026) and controls (P = 0.037). NT-proBNP in contrast
did not show a diurnal rhythm, while melatonin and cortisol patterns were intact in all subjects.
Conclusions sST2 exhibits a diurnal rhythm with lower values in the morning than in the late afternoon. This new insight
could lead to refinement of its diagnostic and prognostic values through specified and consistent sampling times with repeated
measurements. For example, by measuring sST2 during the afternoon, when levels are at their highest, false negatives on
prognosis prediction could be avoided.
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Introduction
Biomarkers are crucial components of clinical decision making
as well as monitoring disease state and progression. Natri-
uretic peptides [B-type natriuretic peptide (BNP) and
N-terminal pro-BNP (NT-proBNP)] are an important part of
the guidelines for diagnosing heart failure (HF). Soluble sup-
pression of tumorigenicity-2 (sST2) recently emerged as a
promising prognostic tool for patients already diagnosed with
HF, as well as an aid for risk stratification in identifying those
at risk of mortality and prehospitalization.1 Owing to its prog-
nostic value, sST2 has been listed in the 2013 American
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guidelines as an important biomarker for the monitoring of
HF patients.2 However, the use of biomarkers comes with dif-
ferent challenges including analytical and biological variabil-
ity, setting the appropriate cut-off values, and determining
clinically meaningful changes in biomarker concentrations.3
With a cut-off value set at 35 ng/mL, sST2 utilization has
been shown to predict outcomes as well as to monitor and
optimize therapy owing to its rapid concentration change
with changing disease state.1 An enzyme-linked immunosor-
bent assay has been developed by Critical Diagnostics (Pre-
sage ST2) for quantitative measurement of sST2,4 which,
with coefficient of variation (CV) < 5%, has a high technical
precision even when it comes to scarce analyte concentra-
tions. Furthermore, age, elevated body mass index, or im-
paired renal function do not significantly affect sST2 values,
while remaining common confounding situations for natri-
uretic peptide measurements.
Biological variation has been determined for sST2 values
by means of serial measurements within the same subject
over prolonged time periods only (e.g. days and months).
However, while accumulating evidence has emphasized the
importance of the circadian (24 h) clock in human physiology
and pathophysiology,5,6 sST2 variation within a 24 h period is
currently unknown. The role of circadian rhythms has also
been confirmed in each type of cardiovascular tissues,
influencing its normal function (e.g. heart rate and blood
pressure) as well as the onset and severity of disease (e.g.
myocardial infarction).7 Therefore, sST2 as a marker and pos-
sibly mediator of cardiac pathology might also be governed
by the circadian clock.
Knowledge of the 24 h pattern in sST2 levels could have
important consequences for its diagnostic and prognostic
usage in clinic, by pinpointing one or several time points in
a 24 h period necessary for valid assessment of disease and
treatment. In addition, the existence of such a 24 h pattern
may elucidate potential mechanistic aspects of the disease–
biomarker interaction.
In this study, to our knowledge for the first time,
within-day variations of sST2 levels are assessed in patients
with HF with reduced ejection fraction (HFrEF) and healthy
controls. 24 h variations of NT-proBNP were previously
investigated,8 thereby serving as a control biomarker for
our cohorts. Melatonin and cortisol were used as a control
for circadian rhythms within our groups.9
Methods
Study design and participants
The study was conducted according to the principles of the
Declaration of Helsinki (64th WMA General Assembly,
Fortaleza, Brazil, October 2013) and in accordance with the
Medical Research Involving Human Subjects Act (WMO). It
was approved by the Medical Ethics Committee of University
Medical Centre Utrecht (Study Number 14/471).
Study participants were admitted to the University Medical
Centre Utrecht. All provided written informed consent after
which the blood withdrawal and biomarker analysis com-
menced (Figure S1). Furthermore, for each individual patient,
health status was established based on electronic health re-
cords within a 12 month period after the blood withdrawal.
For 1/16 control subject, the first time point (9 a.m.) is
missing owing to problems with blood withdrawal.
Laboratory measurements
At seven subsequent time points (9 a.m., 1 p.m., 5 p.m., 9
p.m., 1 a.m., 5 a.m., and 9 a.m.), SST tubes (BD) were used
to collect blood from an intravenous cannula (5 mL per time
point). After collection, serum was separated by centrifuga-
tion and stored at 80°C until analysis. After all samples from
all subjects had been collected, sST2 was quantitatively mea-
sured in triplicates by using the Presage® ST2 sandwich
monoclonal immunoassay (Critical Diagnostics, San Diego,
CA), according to the manufacturer’s protocol. NT-proBNP
was measured on a Cobas e411 analyzer using the Elecsys®
NT-proBNP immunoassay (Roche Diagnostics, Indianapolis).
Analysis of serum melatonin and cortisol concentrations was
performed on liquid chromatography–tandem mass
spectrometer.10
Statistical analysis
Differences between the baseline characteristics of the two
groups were compared by using Mann–Whitney U test, in-
dependent Student’s t test, or Fisher’s exact test, as appro-
priate. One-sample non-parametric binomial test was used
to test the chance of non-randomness of sST2 and
NT-proBNP concentrations peaking at daytime or night-
time. The range spread (%) was used to describe
within-person difference between maximum and minimum
values, calculated by dividing the range (difference between
maximum and minimum) by the minimum value. Circadian
parameters were calculated with cosinor analysis-based
script in statistics software program R. In this program, a
cosinor curve with a period of ~24 h that best fits the pro-
vided data is obtained by linear regression.11 Throughout
the manuscript, the following indications for significance
were used: *P < 0.05 and **P < 0.01. All the analyses
were performed in IBM SPSS Statistics (v. 23), and graphs
were made in Adobe Illustrator CC (19.2.0).
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Results
Patient characteristics
Thirty-two subjects were enrolled in the study: 16 patients
with HFrEF (left ventricular ejection fraction < 40% by echo-
cardiography), and 16 control subjects (Table S1). Baseline
characteristics of all study participants are summarized in
Table 1. The majority of participants were male (81.3% for
patients and 75.0% for controls) with a mean age of 59 ±
13 years for patients and 54 ± 16 for controls. Among the
enrolled patients, 75.0% were in New York Heart Associa-
tion (NYHA) class III and 25.0% in NYHA class II. Outcomes
after 1 year are shown in Table S2.
Circulating soluble suppression of
tumorigenicity-2 exhibits distinct day and night
variations
Peak sST2 values grouped clearly based on sampling time in
the majority of subjects (Figure 1): 81.3% (P = 0.021) of pa-
tients and 93.8% (P = 0.001) of controls had their maximum
sST2 concentrations during the day, while minimum concen-
trations were usually observed during night-time for both pa-
tients (87.5%; P = 0.004) and controls (81.3%; P = 0.021)
(Figure 1A, B). Per subject, range spread of sST2 concentration
spanned from a minimum of 7.8% to a maximum of 34.2% for
patients (19.4% on average, n = 16) (Table 2), and 9.6% to
60.9% for controls (23.5% on average, n = 16) (data not
shown). Taken together, both groups had their highest con-
centrations during daytime (modal value: 5 p.m. for 13/32 sub-
jects; 1 p.m. for 9/32), declining towards their lowest values
during the night (modal value: 5 a.m., for 18/32 subjects).
Among patients, of the three (18.8%) that deviated from the
normal 24 h distribution of sST2 concentration (i.e. had their
peak at night-time instead of daytime), one was in palliative
setting of end-stage HF, the second recently had an implant-
able cardioverter–defibrillator (ICD)-induced shock, and the
third was on high-dose prednisone, which is known to affect
the circadian clock.9 These patients were included in all base-
line tables and primary data analyses (n = 16), but cosinor anal-
ysis for both sST2 and NT-proBNP was also performed without
these three outliers to exclude confounding effects of severe
clock disruption (indicated by n = 13).
In order to visualize the overall diurnal patterns of patients
with different absolute values, we also analysed normalized
sST2 concentrations. Again, we observed a striking gradual
decline from daytime values towards the night: a cosinor
analysis of serum sST2 levels revealed cosine shaped 24 h
oscillations in mean normalized values of HF patients
(P = 0.026 for n = 13; P = 0.072 for n = 16) and controls
(P = 0.037, n = 16) (Figure 1C, D, and Figure S2).
Table 1 Baseline characteristics of study participants
Characteristics All subjects (n = 32) Patients (n = 16) Controls (n = 16) P value
Age (years) 57 ± 15 59 ± 13 54 ± 16 *0.310
Male sex (%) 78.1 81.3 75.0 1.000
BMI (kg/m2) 24.6 ± 3.9 24.8 ± 4.5 24.5 ± 3.3 †0.847
Smoking (%) 53.1 75.0 31.1 0.032
Alcohol (IU/week) 50.0 43.8 56.3 0.724
CKD-EPI GFR
(mL/min/1.73 m2)
66 ± 14 64± 22 69 ± 13 †0.501
Comorbidities (%) Diabetes mellitus 15.6 31.3 0.0 0.018
Myocardial infarction 15.6 25.0 6.3 0.600
Atrial flutter/fibrillation 18.8 37.5 0.0 0.018
Medication (%) ACE inhibitor 31.3 50.0 12.5 0.054
Angiotensin receptor
antagonist
18.8 25.0 12.5 0.654
Antimineralocorticoid 34.4 68.8 0.0 <0.001









NYHA class II 25.0
NYHA class III 75.0
Ejection fraction (%) 23.0 ± 7
Values are mean ± standard deviation or percentage. Continuous variables were tested for normal distribution using skewness and
kurtosis. Differences between groups were studied by the *Mann–Whitney U test, or †independent Student’s t test or Fisher’s exact test,
as appropriate, with P < 0.05 as a cut-off for significance.
ACE inhibitor, angiotensin-converting-enzyme inhibitor; BMI, body mass index; CKD-EPI GFR, the estimated glomerular filtration rate
calculated with the Chronic Kidney Disease Epidemiology Collaboration equation21; IU, international unit; NYHA class, New York Heart
Association functional classification of heart failure severity22; pack-year, 1 year of smoking 20 cigarettes per day.
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Circulating N-terminal pro-B-type natriuretic
peptide fluctuates randomly within a 24 h period
in heart failure with reduced ejection fraction
patients and controls
Differences between minimum and maximum values of
NT-proBNP ranged up to 76.5% in HFrEF patients within 24
h (Table S3). NT-proBNP concentration did not follow a diur-
nal pattern in either of the two groups, fluctuating randomly
within a day (Figure 2). In HFrEF patients, distributions of
maximum and minimum values on average were almost
equally divided over day and night. During the day,
NT-proBNP concentration reached its peak values in 56.3%
and nadir in 43.8% of patients, while a similar peak/nadir
prevalence was observed during the night (peak in 43.8% of
patients, P = 0.804; and nadir in 56.3%, P = 0.804) (Figure
2A). In controls, peaks were reached in 75.0% during the
day and 25.0% during the night (P = 0.077), while nadir values
appeared during the day in 31.3% and during the night 68.8%
(P = 0.210) (Figure 2B). Random distribution of maximum and
Figure 1 sST2 biomarker exhibits a diurnal rhythm in heart failure patients and controls. (A) Percentage of HFrEF patients (n = 16) who have their
maximum and minimum sST2 values (ng/mL) during either the day (9 a.m., 1 p.m., and 5 p.m.) or night (9 p.m., 1 a.m., and 5 a.m.). (B) Percentage
of controls (n = 16) who have their maximum and minimum sST2 values (ng/mL) during either the day (9 a.m., 1 p.m., and 5 p.m.) or night (9 p.m.,
1 a.m., and 5 a.m.). (C) Cosinor analysis of normalized sST2 (ng/mL) per each HFrEF patient (mean ± SEM), in a period of 24 h. Per subject, each time
point was normalized against its mean sST2 value of the entire day (n = 13). (D) Cosinor analysis of normalized sST2 (ng/mL) per each control (mean ±
SEM), in a period of 24 h. Per subject, each time point was normalized against its mean sST2 value of the entire day (n = 16). Horizontal bars indicate
day (white) and night (black). One-sample non-parametric binomial test was used to test the chance of non-randomness of sST2 concentrations
peaking at daytime or night-time. P< 0.05 was used as a cut-off for significance. *P< 0.05 and **P< 0.01. R2 indicates the proportion of the variance
explained by the 24 h variation. Dashed red line represents a fitted cosine curve. HFrEF, heart failure with reduced ejection fraction; sST2, soluble sup-
pression of tumorigenicity-2.
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minimum values throughout the 24 h period was also noted
on mean normalized NT-proBNP concentrations (pg/mL)
where cosinor rhythmicity was assessed using a fitted cosinor
model in HFrEF patients and controls and showed no signifi-
cance (P = 0.091 for n = 13; P = 0.096 for n = 16 patients; P
= 0.093 for n = 16 controls) (Figure 2C, 2D, and Figure S3).
The non-circadian, non-repeating pattern is especially appar-
ent from the very different 9 a.m. values that should be
roughly the same in datasets with circadian distribution. Ob-
tained data were in line with previously published studies in
which no circadian or diurnal rhythm was found in circulating
NT-proBNP.8
Robust circadian markers remain normal in heart
failure patients and controls
Serum melatonin and cortisol patterns within the 24 h period
were as expected in all of 36 subjects, regardless of the pres-
ence or absence of HF (Figure 3). Melatonin was consistently
low during daytime in both groups, with the highest concen-
trations during the night (modal value: 5 a.m.), while cortisol
had diametrically opposite values and peaked during the
early morning (modal value: 9 a.m.). Distribution of peak
times for both hormones is listed in Table S4.
Discussion
In this study, we provide new insights in so far uninvestigated
circadian properties of circulating sST2 levels in HF patients.
In the vast majority of subjects, sST2 concentration reached
its peak in the afternoon, with the lowest levels during the
night-time. Knowledge of this diurnal variation will lead to im-
proved usage of sST2 as a prognostic biomarker.
Circadian rhythms in cardiovascular (patho)
physiology
The importance of circadian rhythms in cardiovascular
health and disease has been recognized and emphasized
in many studies to date. We recently provided an
in-depth explanation of circadian biology and its interplay
with cardiovascular function and dysfunction.7 Briefly, func-
tional circadian rhythms have been found in every cell type
within the cardiovascular system, influencing its function in
many ways; from vascular tone, heart rate, blood pressure,
signalling, and cardiac metabolism to thrombus for-
mation, onset of myocardial infarction, and arrhythmias.
Therefore, it does not come as a surprise that certain
cardiovascular-related biomarkers are also under direct or
indirect influence of the clock and exhibit day and night
fluctuations.
The goal of the study was to investigate whether sST2 ex-
hibits circadian variation in patients with HFrEF and controls
without cardiovascular disease. While the existence of a circa-
dian rhythm in sST2 serum concentrations was unknown, it
has been previously investigated for other biomarkers. For
example, cardiac troponin T was shown to exhibit
non-random diurnal variation,12 while predictable daily fluc-
tuations were absent in NT-proBNP8 and cardiac troponin
I13 levels. Serving as a negative control in our study,
NT-proBNP fluctuated randomly throughout the day and
Table 2 Twenty-four-hour range of soluble suppression of tumorigenicity-2 concentration (ng/mL) in individual heart failure with re-
duced ejection fraction patients
Patient number Maximum (ng/mL) Minimum (ng/mL) Range (ng/mL) Range spread (%)
1 101.9 94.5 7.4 7.8
2 35.9 32.5 3.4 10.3
3 37.1 33.2 3.9 11.7
4 19.2 16.9 2.3 13.9
5 25.6 22.5 3.1 13.9
6 47.8 41.9 5.9 14.1
7 62.7 53.9 8.9 16.5
8 101.9 87.4 14.5 16.6
9 65.9 55.6 10.2 18.4
10 54.6 45.5 9.1 19.9
11 21.6 17.7 3.9 22.0
12 64.2 51.5 12.8 24.8
13 65.4 51.1 14.3 27.9
14 33.2 25.8 7.4 28.6
15 71.4 55.3 16.1 29.2
16 33.1 24.7 8.4 34.2
Maximum= highest measured sST2 concentration (ng/mL) in 24 h period. Minimum= lowest measured sST2 concentration (ng/mL) in 24
h period. Range = maximum–minimum. Range spread = range/minimum. Patients in which maximum and minimum sST2 values fluctu-
ate above and below 35 ng/mL cut-off value are indicated in bold.
HFrEF, heart failure with reduced ejection fraction; sST2, soluble suppression of tumorigenicity-2.
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indeed did not exhibit any rhythmicity in HF patients or con-
trols. Concentrations of melatonin and cortisol, robust circa-
dian markers, were measured to serve as positive controls
of internal circadian rhythms, with cortisol levels peaking dur-
ing the day and melatonin levels during the night. Observed
data were in line with expected rhythmic behaviour of these
main endocrine products of the central clock,9 pointing to
preserved neurohumoral circadian output in both subject
groups.
Diurnal oscillation of soluble suppression of
tumorigenicity-2 biomarker
To the best of our knowledge, this is the first record of the
diurnality of circulating sST2 concentrations, resulting in im-
portant implications for clinical usage in terms of prognosis
and therapy guidance (Figure 4). Circulating sST2, reflecting
stress brought upon myocardial injury and adverse remodel-
ling, recently emerged as a strong predictor of HF outcome.
Figure 2 NT-proBNP biomarker fluctuates randomly within a day in heart failure patients and controls. (A) Percentage of HFrEF patients (n = 16) who
have their maximum and minimum NT-proBNP values (pg/mL) during either the day (9 a.m., 1 p.m., and 5 p.m.) or night (9 p.m., 1 a.m., and 5 a.m.). (B)
Percentage of controls (n = 16) who have their maximum and minimum NT-proBNP values (pg/mL) during either the day (9 a.m., 1 p.m., and 5 p.m.) or
night (9 p.m., 1 a.m., and 5 a.m.). (C) Cosinor analysis of normalized NT-proBNP (pg/mL) per each HFrEF patient (mean ± SEM), in a period of 24 h. Per
subject, each time point was normalized against its mean NT-proBNP value of the entire day (n = 13). (D) Cosinor analysis of normalized NT-proBNP
(pg/mL) per each control (mean ± SEM), in a period of 24 h. Per subject, each time point was normalized against its mean NT-proBNP value of the
entire day (n = 16). Horizontal bars indicate day (white) and night (black). One-sample non-parametric binomial test was used to test the chance of
non-randomness of NT-proBNP concentrations peaking at daytime or night-time. P < 0.05 was used as a cut-off for significance. R2 indicates the pro-
portion of the variance explained by the 24 h variation. HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal pro-B-type natri-
uretic peptide.
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Indeed, within our HFrEF patients, the majority of patients
with mean sST2 values higher than 35 ng/mL either died or
suffered from another major adverse outcome. For detailed
description of sST2 biology and its role in mediating myocar-
dial strain, as well as in the development of vascular disease,
the reader is referred to recently published review arti-
cles.14,15 sST2, acting as a decoy receptor for IL-33 and
thereby inhibiting its beneficial cardioprotective effects, is im-
plicated in cardiac and vascular remodelling. As favourable ef-
fects of IL-33 are blocked with the abnormal quantities of
sST2 in circulation, measurement of sST2 concentration has
proven useful in providing prognostic information for various
cardiovascular disorders.
Aside from its prognostic value, sST2 could be used to
monitor treatment effect and subsequently guide therapy;
it was previously shown that patients with reduction of
sST2 concentration in response to drug treatment had better
outcomes than those with continued sST2 values > 35 ng/mL
during the entire study period.16 Notably, biomarkers are in-
creasingly used in clinical HF trials as an inclusion criterion,
surrogate endpoint, and target for therapy.17 Thus, a rise or
fall in sST2 concentration caused by physiological diurnal var-
iation may lead to misinterpretation of treatment effect,
overestimation or underestimation of prognostic warning
signs, and confounding of clinical trial outcomes. It is there-
fore of importance to take into account at what time the
blood sample was taken.
Interestingly, while the diurnal pattern of sST2 concentra-
tion was remarkably consistent across sex, age, and other
baseline characteristics (Table 1), our data indicate that
end-stage HF in palliative setting, recent ICD-induced shock,
and high-dose prednisone can lead to changes in peak time
of sST2 levels. Thus, while the existence of physiological diur-
nal variation of sST-2 levels can have an important impact on
clinical decision making, a deviating 24 h pattern may also
have predictive value.
Figure 3 Study subjects exhibit normal melatonin and cortisol patterns. Within-day distribution of (A) melatonin (pmol/L) and (B) cortisol concentra-
tion (nmol/L) in heart failure patients (mean ± SEM). Within-day distribution of (C) melatonin (pmol/L) and (D) cortisol concentration (nmol/L) in con-
trol subjects (mean ± SEM). Horizontal bar indicates day (white) and night (black). HFrEF, heart failure with reduced ejection fraction.
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Clinical outlook
Although sST2 is yet to be implemented in the clinic as a
standard of care, it has already proven to be a robust prog-
nostic biomarker for both chronic and acute HFrEF.14 As pre-
viously mentioned, the currently applied cut-off value of sST2
in chronic HF is 35 ng/mL; however, reached consensus did
not take into consideration possible biological 24 h variation
of its concentration.18 Our study provides the first evidence
for circadian rhythmicity of sST2, implying that time of day
may be an important variable when determining sST2 levels.
Therefore, clinicians are advised to be cautious while
interpreting sST2 values, because a result just under 35
ng/mL in the morning may exceed this threshold in the after-
noon. In Table 2, we show examples of this phenomenon in
two patients.
Because of the diurnal rhythm of sST2, it would be recom-
mended to measure sST2 during the afternoon, when sST2
levels are commonly at their highest, if the aim is to provide
maximal negative predictive value and assure patient safety.
Future studies re-evaluating the cut-off value of sST2 taking
sample timing into account may further improve sST2 as a
prognostic tool.
Finally, the average range spread of sST2 concentrations
found in our patient group was 19.4%, with a maximum range
spread of 34.2% in 24 h. Therefore, when using serial sST2
levels to assess the efficacy of initiated HF therapy and refine
prognostic value,16 samples should ideally be taken around
the same hour or corrected for time of day as much as possi-
ble. For example, a first measurement in the afternoon and a
follow-up measurement in the morning (yielding a lower sST2
concentration) may suggest an improvement in the patient’s
condition and a good therapeutic response, while in fact it
demonstrates circadian fluctuation.
Study limitations
This study did not make use of standardized conditions for
physical activity, meals, light exposure, and sleep duration,
Figure 4 Influence of diurnal rhythms on clinical interpretation of sST2 biomarker. Knowledge about the diurnal variation of sST2 concentration is
needed for proper timing of measurements and their interpretation. Prognostic and diagnostic value of sST2 levels, as well as therapy optimization,
should be refined by applying specified sampling times and repeated measurements. IL-33, interleukin-33; sST2, soluble suppression of tumorigenic-
ity-2; ST2L, suppression of tumorigenicity-2 ligand.
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as is commonly done for clinical circadian experiments in or-
der to achieve a more comparable circadian rhythm between
subjects.12 Nevertheless, our set-up makes the study clinically
more translatable, as patients usually do not follow an exter-
nally imposed food/activity regimen. This way, all consistent
differences found within daily levels of investigated bio-
markers prove to be highly robust, if evident without a con-
trolled environmental setting.
Another limitation of this study lies in the groups assem-
bly, as the majority of the participants were of the male
gender (78.1% of total participants). Coglianese et al. found
a significant difference in sST2 levels between men and
women,19 with higher concentrations noted in men. In our
data, we observed similar diurnal patterns in men and
women, but the relatively low number of women precludes
definite conclusions on comparisons between both sexes.
Furthermore, smoking has been shown to increase IL-33
concentrations in the airway epithelium as well as to alter
the ST2 expression pattern in the lung.20 A positive smoking
status was reported in 53.1% of our subjects, however, with
no obvious effect on the diurnality of sST2. Despite these
limitations, the goal of our study, which was to observe diur-
nal differences within daily sST2 levels, was not affected and
even strengthened.
Finally, sample size of the study was relatively low (n = 16
for each group), and three patients were excluded from the
cosinor analysis owing to the severe clock disruption. How-
ever, this was sufficient to provide the first evidence for a
diurnal pattern of sST2 expression. The uniqueness of this
study lies in the repeated sST2 measurements during a 24 h
period within each study participant. Even though the final
number of included patients and controls is modest, sST2
measurements during seven time points per each
patient/control provide a resolution that has not been re-
ported before in ST2 and HF research.
Conclusions
Biomarker sST2 concentrations exhibit significant diurnal
variation with predictable peak and trough times, a novel
finding that has consequences for the clinical interpretation
of sST2 levels in HF patients. Besides its impact on clinical
management and clinical trials, the within-day fluctuation
of sST2 also gives hints for further investigation into its
mechanism of action. Presumably, sST2-driven inhibition of
the cardioprotective IL-33–ST2L pathway also has a
time-dependent character. While clinical significance is cov-
ered within the content of this study, biological importance
is yet to be determined, potentially leading towards novel
therapeutic strategies.
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